Hamel Lawrence G 4
4 · ACELRX PHARMACEUTICALS INC · Filed Nov 5, 2018
Insider Transaction Report
Form 4
Hamel Lawrence G
Chief Development Officer
Transactions
- Award
Common Stock
2018-11-02$2.23/sh+5,000$11,125→ 34,795 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2018-11-02$5.00/sh−5,000$25,000→ 29,795 total(indirect: By Trust) - Award
Stock Option (Right to Buy)
2018-11-02+26,125→ 26,125 totalExercise: $2.23From: 2018-11-02Exp: 2028-11-02→ Common Stock (26,125 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2018-11-02−5,000→ 21,125 totalExercise: $2.23From: 2018-11-02Exp: 2028-11-02→ Common Stock (5,000 underlying)
Holdings
- 24,371
Common Stock
Footnotes (2)
- [F1]Shares sold pursuant to a 10b5-1 plan.
- [F2]On April 7, 2018, the reporting person was granted an option to purchase 52,250 shares of common stock. The option vests in two equal annual installments based on Company's achievement of commercial approval by the U.S. Food and Drug Administration ("FDA") of its new drug application for "DSUVIA" on or before February 15, 2019; and the remaining 50% of the award shall vest on the one-year anniversary of the date of such FDA approval, in all cases subject to continuous service to the Company. The performance criteria for commercial approval by the FDA for DSUVIA was met on November 2, 2018, resulting in vesting of the option as to 26,125 shares.